147290-69-5

Basic information

• Product Name: t-butyl 4-nitro-3-[N-(t-butyloxycarbonyl)-N-(2-phenyl-ethyl)aminomethyl]benzoate
• Synonyms: t-butyl 4-nitro-3-[N-(t-butyloxycarbonyl)-N-(2-phenyl-ethyl)aminomethyl]benzoate
• CAS NO: 147290-69-5
• Molecular Weight: 456.539
• Mol File: 147290-69-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: t-butyl 4-nitro-3-[N-(t-butyloxycarbonyl)-N-(2-phenyl-ethyl)aminomethyl]benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: t-butyl 4-nitro-3-[N-(t-butyloxycarbonyl)-N-(2-phenyl-ethyl)aminomethyl]benzoate(147290-69-5)
• EPA Substance Registry System: t-butyl 4-nitro-3-[N-(t-butyloxycarbonyl)-N-(2-phenyl-ethyl)aminomethyl]benzoate(147290-69-5)

Safety Data

• Hazardous Substances Data: 147290-69-5(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 147290-68-4 t-butyl 4-nitro-3-[N-(2-phenylethyl)aminomethyl]benzoate 
• 3113-71-1 3-methyl-4-nitrobenzoic acid 
• 171049-67-5 tert-butyl-3-(bromomethyl)-4-nitrobenzoate 
• 147290-67-3 tert-butyl 3-methyl-4-nitrobenzoate 
• 64-04-0 phenethylamine 

Downstream Products

• 171049-45-9 [7-(4-{Amino-[(Z)-benzyloxycarbonylimino]-methyl}-phenylcarbamoyl)-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl]-acetic acid methyl ester 
• 147290-71-9 2-{4-tert-Butoxycarbonyl-2-[(tert-butoxycarbonyl-phenethyl-amino)-methyl]-phenylamino}-succinic acid dimethyl ester 
• 292135-38-7 [7-(4-Carbamimidoyl-phenylcarbamoyl)-3-oxo-4-phenethyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl]-acetic acid methyl ester 
• 171049-34-6 methyl 7-carboxy-3-oxo-1,4-benzodiazepine-2-acetate 
• 147290-70-8 tert-butyl 4-amino-3-[[N-(tert-butoxycarbonyl)-N-phenethylamino]methyl]benzoate 

Relevant articles and documents

Fab I inhibitors

Compounds of the formula (I) are disclosed which are FabI inhibitors and are useful in the treatment of bacterial infections.

Bicyclic fibrinogen antagonists

This invention relates to compounds of the formula: STR1 wherein A1 to A5 form an accessible substituted seven-membered ring, which may be saturated or unsaturated, optionally containing up to two heteroatoms chosen from the group of O, S and N wherein S and N may be optionally oxidized; D1 to D4 form an accessible substituted six membered ring, optionally containing up to two nitrogen atoms; R is at least one substituent chosen from the group of R7, or Q--C1-4 alkyl, Q--C2-4 alkenyl, Q--C2-4 alkynyl, preferably substituted by an acidic function; R* is H, Q--C1-6 alkyl, Q--C1-6 oxoalkyl, Q--C2-6 alkenyl or Q--C2-4 alkynyl, C3-6 cycloalkyl, Ar or Het, optionally substituted by one or more substitutents; and R6 is preferably a substituent containing a basic nitrogen moiety; or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.